Amplify Treatments, Testing and Advancements ETF (NYSEARCA:GERM – Get Free Report)’s stock price dropped 1.3% during trading on Thursday . The company traded as low as $18.38 and last traded at $18.38. Approximately 1,048 shares were traded during trading, a decline of 51% from the average daily volume of 2,146 shares. The stock had previously closed at $18.62.
Amplify Treatments, Testing and Advancements ETF Stock Performance
The firm has a market cap of $10.02 million, a PE ratio of 7.10 and a beta of 1.08. The company’s 50-day simple moving average is $18.57 and its two-hundred day simple moving average is $18.51.
About Amplify Treatments, Testing and Advancements ETF
The ETFMG Treatments, Testing and Advancements ETF (GERM) is an exchange-traded fund that mostly invests in health care equity. The fund tracks a tier-weighted, narrow index of US-listed, global biotech companies that are engaged in the testing and treatments of infectious diseases. GERM was launched on Jun 17, 2020 and is managed by ETF Managers Group.
Read More
- Five stocks we like better than Amplify Treatments, Testing and Advancements ETF
- What Are Dividend Challengers?
- What’s Behind Walgreens Stock Plunge: What Investors Can Do Next
- With Risk Tolerance, One Size Does Not Fit All
- MarketBeat Week in Review – 6/24 – 6/28
- The Role Economic Reports Play in a Successful Investment Strategy
- General Mills Stock Drops After Revenue Miss in Fiscal Q4 2024
Receive News & Ratings for Amplify Treatments Testing and Advancements ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amplify Treatments Testing and Advancements ETF and related companies with MarketBeat.com's FREE daily email newsletter.
